Heart regeneration after myocardial infarction using synthetic biomaterials
Pascual-Gil S (1), Garbayo E (1), Díaz-Herráez P (1), Prosper F (2), Blanco-Prieto MJ (3).
(1) Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
(2) Hematology, Cardiology and Cell Therapy, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain; Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain.
(3) Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain
Myocardial infarction causes almost 7.3 million deaths each year worldwide. However, current treatments are more palliative than curative. Presently, cell and protein therapies are considered the most promising alternative treatments.
Clinical trials performed until now have demonstrated that these therapies are limited by protein short half-life and by low transplanted cell survival rate, prompting the development of novel cell and protein delivery systems able to overcome such limitations.
In this review we discuss the advances made in the last 10years in the emerging field of cardiac repair using biomaterial-based delivery systems with focus on the progress made on preclinical in vivo studies.
Then, we focus in cardiac tissue engineering approaches, and how the incorporation of both cells and proteins together into biomaterials has opened new horizons in the myocardial infarction treatment. Finally, the ongoing challenges and the perspectives for future work in cardiac tissue engineering will also be discussed.
CITATION J Control Release. 2015 Apr 10;203:23-38. doi: 10.1016/j.jconrel.2015.02.009. Epub 2015 Feb 7.